Aker BioMarine (AKBM) Stock Overview
A biotech innovator, develops and supplies krill-derived products for consumer health and wellness worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for AKBM from our risk checks.
AKBM Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Aker BioMarine ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 83.80 |
| 52 Week High | NOK 94.30 |
| 52 Week Low | NOK 43.65 |
| Beta | 0.36 |
| 1 Month Change | -2.33% |
| 3 Month Change | 3.58% |
| 1 Year Change | 67.94% |
| 3 Year Change | 124.06% |
| 5 Year Change | -4.77% |
| Change since IPO | -19.96% |
Recent News & Updates
Would Aker BioMarine (OB:AKBM) Be Better Off With Less Debt?
Sep 28
There's Reason For Concern Over Aker BioMarine ASA's (OB:AKBM) Price
Aug 20Recent updates
Would Aker BioMarine (OB:AKBM) Be Better Off With Less Debt?
Sep 28There's Reason For Concern Over Aker BioMarine ASA's (OB:AKBM) Price
Aug 20Need To Know: The Consensus Just Cut Its Aker BioMarine ASA (OB:AKBM) Estimates For 2025
May 03Aker BioMarine ASA's (OB:AKBM) CEO Compensation Looks Acceptable To Us And Here's Why
Apr 19Is Aker BioMarine (OB:AKBM) Using Too Much Debt?
Feb 15
Partnerships In Japan And China Will Expand Kori Brand's International Reach
Divesting Understory should streamline operations and enhance net margins, as the company refocuses on core segments like Human Health Ingredients.Aker BioMarine AS' (OB:AKBM) Share Price Boosted 34% But Its Business Prospects Need A Lift Too
Dec 20Aker BioMarine (OB:AKBM) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Nov 08Aker BioMarine AS' (OB:AKBM) Revenues Are Not Doing Enough For Some Investors
Nov 05At kr102, Is It Time To Put Aker BioMarine AS (OB:AKBM) On Your Watch List?
Aug 20Optimistic Investors Push Aker BioMarine AS (OB:AKBM) Shares Up 25% But Growth Is Lacking
Jul 19What Does The Future Hold For Aker BioMarine AS (OB:AKBM)? These Analysts Have Been Cutting Their Estimates
Jul 16There Are Reasons To Feel Uneasy About Aker BioMarine's (OB:AKBM) Returns On Capital
Jul 11These 4 Measures Indicate That Aker BioMarine (OB:AKBM) Is Using Debt In A Risky Way
Jun 03There's No Escaping Aker BioMarine AS' (OB:AKBM) Muted Revenues
Feb 15There Are Reasons To Feel Uneasy About Aker BioMarine's (OB:AKBM) Returns On Capital
Nov 06Estimating The Fair Value Of Aker BioMarine AS (OB:AKBM)
Sep 06We Think You Should Be Aware Of Some Concerning Factors In Aker BioMarine's (OB:AKBM) Earnings
Nov 04Aker BioMarine AS' (OB:AKBM) Has Found A Path To Profitability
Apr 13Aker BioMarine AS (OB:AKBM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 18Shareholder Returns
| AKBM | NO Food | NO Market | |
|---|---|---|---|
| 7D | 0.2% | 0.6% | 0.8% |
| 1Y | 67.9% | 0.6% | 7.5% |
Return vs Industry: AKBM exceeded the Norwegian Food industry which returned 0.6% over the past year.
Return vs Market: AKBM exceeded the Norwegian Market which returned 7.5% over the past year.
Price Volatility
| AKBM volatility | |
|---|---|
| AKBM Average Weekly Movement | 4.4% |
| Food Industry Average Movement | 4.1% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in NO Market | 10.9% |
| 10% least volatile stocks in NO Market | 2.6% |
Stable Share Price: AKBM has not had significant price volatility in the past 3 months compared to the Norwegian market.
Volatility Over Time: AKBM's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 249 | Matts Johansen | www.akerbiomarine.com |
Aker BioMarine ASA, a biotech innovator, develops and supplies krill-derived products for consumer health and wellness worldwide. It operates through three segments: Human Health Ingredients (HHI), Consumer Health Products, and Emerging Business. The Human Health Ingredients segment sells B2B krill oil supplements for humans under the Superba Krill brand; supplements for brain health under the LYSOVETA brand; and marine-origin DHA omega-3 from microalgae under the Revervia brand name, as well as advanced phospholipid technology under PL+ name.
Aker BioMarine ASA Fundamentals Summary
| AKBM fundamental statistics | |
|---|---|
| Market cap | NOK 7.29b |
| Earnings (TTM) | -NOK 120.74m |
| Revenue (TTM) | NOK 2.16b |
Is AKBM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AKBM income statement (TTM) | |
|---|---|
| Revenue | US$214.20m |
| Cost of Revenue | US$130.80m |
| Gross Profit | US$83.40m |
| Other Expenses | US$95.40m |
| Earnings | -US$12.00m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.14 |
| Gross Margin | 38.94% |
| Net Profit Margin | -5.60% |
| Debt/Equity Ratio | 128.0% |
How did AKBM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/12 18:11 |
| End of Day Share Price | 2025/11/12 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aker BioMarine ASA is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Stein Aukner | DNB Carnegie |
| Ola Trovatn | DNB Carnegie |